A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.

Rana R McKayKatharina LeuchtWanling XieOpeyemi JegedeDavid A BraunMichael B AtkinsMarc-Oliver GrimmToni K Choueiri

Published in: The oncologist (2023)

A small subset of patients lacking a response to nivolumab derive benefit from salvage nivolumab plus ipilimumab. When possible, both drugs should be given in concomitantly, rather in an adaptive fashion.

Keyphrases

phase ii
renal cell carcinoma
clinical trial
end stage renal disease
ejection fraction
newly diagnosed
open label
prognostic factors
study protocol